Chav Haujlwm Thoob Ntiaj Teb

Thaum Lub Plaub Hlis 25, 2025, InnoCare Pharma tshaj tawm tias nws cov tshuaj tshiab pan-TRK inhibitor zurletrectinib (ICP-723) tau txais kev tshuaj xyuas ua ntej los ntawm Lub Chaw Saib Xyuas Tshuaj (CDE) ntawm Tuam Tshoj National Medical Products Administration (NMPA), uas tau lees txais Daim Ntawv Thov Tshuaj Tshiab (NDA) ntawm z...Nyeem ntxiv»

Thaum Lub Plaub Hlis 25, 2025, Innovent Biologics tshaj tawm tias Tuam Tshoj Lub Chaw Saib Xyuas Khoom Siv Kho Mob Hauv Tebchaws (NMPA) tau pom zoo Daim Ntawv Thov Tshuaj Tshiab (NDA) rau limertinib ua thawj kab kev kho mob rau cov neeg laus uas muaj mob qog nqaij hlav hauv lub ntsws tsis me me (NSCLC) hauv zos lossis metastatic ...Nyeem ntxiv»

Thaum Lub Plaub Hlis 23, Akeso's penpulimab tau txais kev pom zoo los ntawm Lub Chaw Saib Xyuas Khoom Noj thiab Tshuaj nrog cisplatin lossis carboplatin thiab gemcitabine rau kev kho mob thawj kab ntawm cov neeg laus uas muaj mob qog nqaij hlav tsis-keratinizing nasopharyngeal carcinoma (NPC) rov tshwm sim lossis kis mus rau lwm qhov. FDA kuj tau pom zoo penpulimab-kcqx ua ib qho kev txhaum ...Nyeem ntxiv»

Thaum Lub Peb Hlis 16, 2025, Akeso tshaj tawm tias nws cov tshuaj antibody anti-PD-1 monoclonal tshiab, penpulimab, tau txais kev pom zoo los ntawm National Medical Products Administration (NMPA) rau kev kho mob thawj kab ntawm cov mob qog nqaij hlav nasopharyngeal rov tshwm sim lossis metastatic (NPC) ua ke ...Nyeem ntxiv»

Thaum Lub Plaub Hlis 24, 2025, GenFleet Therapeutics tshaj tawm tias US Food and Drug Administration (FDA) tau pom zoo rau kev tshawb nrhiav tshuaj tshiab (IND) ntawm GFH375 / VS-7375, uas yog ib qho tshuaj KRAS G12D (ON / OFF) inhibitor, rau kev sim tshuaj kho cov neeg mob qog nqaij hlav uas muaj KRAS G12D mutation. Txoj kev tshawb fawb no ...Nyeem ntxiv»

Thaum Lub Plaub Hlis 17, 2025, Hansoh Pharmaceutical tshaj tawm tias Pawg Neeg tus kheej tsim B7-H3-targeted antibody-drug conjugate (ADC) HS-20093 rau kev txhaj tshuaj tau txais kev pom zoo kom suav nrog ua Breakthrough-Therapy-Designated Drug los ntawm National Medical Products Administration (NMPA) ntawm Tuam Tshoj, ...Nyeem ntxiv»

Thaum Lub Plaub Hlis 15, 2025, InnoCare Pharma tshaj tawm tias Lub Chaw Saib Xyuas Kev Tshuaj Xyuas Tshuaj (CDE) ntawm Tuam Tshoj National Medical Products Administration (NMPA) tau txais Daim Ntawv Thov Tshuaj Tshiab (NDA) rau nws tiam tshiab pan-TRK inhibitor zurletrectinib (ICP-723) rau kev kho mob ntawm cov neeg laus thiab cov hluas p ...Nyeem ntxiv»

Tsis ntev los no, GenFleet tshaj tawm cov ntaub ntawv theem II tshiab kawg ntawm kev tshawb fawb KROCUS, fulzerasib (GFH925, KRAS G12C inhibitor) ua ke nrog cetuximab rau kev kho mob qog nqaij hlav ntsws tsis yog me me (NSCLC) thawj kab, hauv kev sau luv luv ntawm kev nthuav qhia me me ntawm 2025 European Lung Cancer Conf ...Nyeem ntxiv»

PLB1004, tsim los ntawm Beijing Avistone Biotechnology Co., Ltd., yog ib qho kev nyab xeeb, xaiv tau zoo heev, thiab ua haujlwm tau zoo irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) siv rau kev kho mob qog nqaij hlav tsis yog me me (NSCLC). Thaum Lub Plaub Hlis 9, 2025, National Medical Products Admi...Nyeem ntxiv»

Thaum Lub Peb Hlis 13, 2025, phau ntawv xov xwm thoob ntiaj teb Nature Medicine tau tshaj tawm MediLink's B7-H3 targeting antibody drug conjugate (ADC) YL201 Theem 1/1b kev sim. Kev sim no suav nrog ib feem ntawm kev nce koob tshuaj (theem 1) thiab ib feem ntawm kev nthuav koob tshuaj (theem 1b). Tag nrho muaj 312 tus neeg mob tau sau npe thoob plaws...Nyeem ntxiv»

Thaum Lub Peb Hlis 21, 2025, Immunofoco tshaj tawm tias nws txoj kev kho mob CAR-T cell EpCAM-targeting autologous, IMC001, tau txais kev tso cai los ntawm Center for Drug Evaluation (CDE) nyob rau hauv National Medical Products Administration (NMPA) hauv Suav teb rau nws qhov kev tshawb nrhiav tshiab thib ob D ...Nyeem ntxiv»

Thaum Lub Peb Hlis 31, 2025, Innovent Biologics tshaj tawm tias Lub Chaw Saib Xyuas Tshuaj (CDE) ntawm Tuam Tshoj Lub Chaw Tswj Xyuas Khoom Siv Kho Mob Hauv Tebchaws (NMPA) tau tso cai rau Breakthrough Therapy Designation (BTD) rau IBI363, thawj-hauv-chav kawm PD-1 / IL-2α-bias bispecific antibody fusion protein, ua monotherapy rau ...Nyeem ntxiv»